Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned a consensus recommendation of “Hold” from the seventeen ratings firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $490.8182.

MEDP has been the subject of several recent analyst reports. Cowen reaffirmed a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 price objective on Medpace in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. BMO Capital Markets started coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price on the stock. Finally, Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th.

Medpace Price Performance

Shares of MEDP opened at $571.02 on Friday. The company has a 50-day moving average of $579.51 and a two-hundred day moving average of $490.69. The stock has a market cap of $16.09 billion, a price-to-earnings ratio of 39.93, a PEG ratio of 1.92 and a beta of 1.43. Medpace has a one year low of $250.05 and a one year high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the previous year, the business earned $3.01 earnings per share. The firm’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other news, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at $3,542,100. The trade was a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 668 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 387,925 shares of company stock valued at $233,386,647 in the last quarter. Company insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC raised its position in Medpace by 2.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after acquiring an additional 19 shares in the last quarter. BOKF NA increased its stake in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares during the last quarter. HighPoint Advisor Group LLC raised its holdings in shares of Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares in the last quarter. Portside Wealth Group LLC lifted its stake in shares of Medpace by 2.5% in the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after purchasing an additional 27 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.